Curated News
By: NewsRamp Editorial Staff
May 23, 2025
NRx Pharmaceuticals Expands Psychiatry Clinics with Kadima Institute Acquisition
TLDR
- HOPE Therapeutics gains a strong foothold in the mental health care sector with the acquisition of Kadima Neuropsychiatry Institute.
- Kadima Neuropsychiatry Institute will serve as the clinical model for HOPE Therapeutics' network of psychiatric clinics across the U.S.
- The acquisition of Kadima Institute will lead to enhanced treatments for suicidal depression and chronic pain, improving mental health care nationwide.
- Kadima Neuropsychiatry Institute integrates cutting-edge treatments like psychedelic medications and TMS, setting a new standard in mental health care.
Impact - Why it Matters
This news matters as it signifies NRx's strategic move into mental health care, aiming to revolutionize treatment methods. The acquisition of Kadima Neuropsychiatry Institute sets the stage for HOPE Therapeutics' nationwide clinic network, potentially impacting the accessibility and quality of psychiatric care in the U.S.
Summary
NRx Pharmaceuticals (NASDAQ: NRXP) and its subsidiary HOPE Therapeutics, Inc., have acquired Kadima Neuropsychiatry Institute in California to expand their network of interventional psychiatry clinics. Dr. David Feifel, Kadima's founder, will join HOPE as Chief Medical Innovation Officer. HOPE aims to acquire 30 clinics by 2025, projecting $100M in revenue.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NRx Pharmaceuticals Expands Psychiatry Clinics with Kadima Institute Acquisition
